Tesamorelin: An FDA-Approved Peptide and Its Off-Label Story

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

Tesamorelin is the only peptide in the current 503A compounding catalog with an unambiguously active FDA approval status. It is marketed under the brand name Egrifta for a specific, narrow medical indication. It is also one of the more widely prescribed peptides in off-label integrative medicine practice, used outside its approved indication on the basis of its mechanism and the published research on its broader pharmacological effects.

This article describes what tesamorelin is, where it came from, what it is approved to treat, and the literature behind its off-label use.

The molecule

Tesamorelin is a synthetic 44-amino-acid peptide modified with a trans-3-hexenoyl group attached to the N-terminus. The 44-amino-acid sequence is identical to endogenous growth hormone-releasing hormone (GHRH). The N-terminal modification extends the compound's plasma half-life by preventing degradation by dipeptidyl peptidase IV, the enzyme that rapidly inactivates native GHRH.1

The half-life extension is the principal pharmacokinetic difference between tesamorelin and sermorelin, the shorter GHRH(1-29) analog discussed elsewhere in this collection. Where sermorelin's half-life is on the order of minutes, tesamorelin's half-life is several hours, supporting once-daily subcutaneous dosing as the standard administration pattern.

Mechanistically, tesamorelin functions as a GHRH receptor agonist on anterior pituitary somatotrophs, producing pulsatile release of endogenous growth hormone in the same fashion as endogenous GHRH and as sermorelin. The receptor pharmacology is the same. The kinetics differ.

The FDA approval history

Tesamorelin received FDA approval in November 2010 under the brand name Egrifta. The approval was sponsored by Theratechnologies, a Canadian pharmaceutical company. The approved indication is the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The indication is narrow and specific to a particular metabolic complication that occurs in some patients receiving certain antiretroviral therapies.2

The approval was based on two phase III clinical trials that demonstrated reductions in visceral adipose tissue (VAT) in HIV-positive patients with lipodystrophy treated with tesamorelin compared to placebo. The primary endpoint in both trials was percent change in VAT as measured by computed tomography. The treatment group showed statistically and clinically meaningful reductions in VAT over the 26-week study period.3

The drug has remained on the US market continuously since its approval. The label has been updated several times to reflect post-marketing safety data and additional clinical findings. Egrifta SV, a more concentrated formulation that simplifies the administration regimen, was approved in 2019.4

The body composition mechanism

The mechanism by which tesamorelin reduces visceral adipose tissue in the studied population involves the downstream effects of growth hormone on lipid metabolism. Growth hormone promotes lipolysis in adipose tissue and shifts substrate utilization toward fat oxidation. The increase in endogenous growth hormone produced by tesamorelin administration produces measurable reductions in VAT, with smaller effects on subcutaneous adipose tissue.5

The selectivity for visceral over subcutaneous fat is a notable feature of the compound's pharmacology. Visceral fat is the metabolically active fat depot most strongly associated with metabolic syndrome, insulin resistance, and cardiovascular risk markers in the general population. The compound's effect on this depot specifically, rather than producing generalized fat loss, is one of the features that has shaped its off-label clinical use outside the HIV lipodystrophy population.

Off-label use in integrative medicine

Off-label use of FDA-approved drugs is a standard feature of US medical practice. Physicians may prescribe approved drugs for indications other than those listed on the FDA label when their clinical judgment supports the use. The label does not restrict prescribing; it restricts the manufacturer's marketing claims. This distinction matters for tesamorelin because the compound's off-label use is substantial.6

In integrative and longevity-oriented medical practice, tesamorelin is prescribed off-label in patients without HIV lipodystrophy, typically for body composition and metabolic concerns in middle-aged and older adults. The clinical rationale is anchored on the compound's documented effects on VAT in the approval trials and on the broader endocrine literature on GHRH analog pharmacology in adult populations.

The off-label clinical literature is smaller than the approval-indication literature, but it is not empty. Several smaller studies have examined tesamorelin's effects on VAT and metabolic markers in non-HIV populations, including studies in patients with nonalcoholic fatty liver disease and in metabolic syndrome cohorts. The findings have been broadly consistent with the mechanism: VAT reductions, modest improvements in some lipid markers, and the usual GHRH analog effects on IGF-1 levels.7

The off-label use should be distinguished from research-chemical channel distribution. Off-label prescribing occurs within the physician-patient-pharmacy relationship and uses FDA-approved or 503A-compounded preparations. Research-chemical distribution operates outside that relationship and is the subject of the FDA enforcement activity discussed elsewhere in this collection.

Safety profile

The tesamorelin safety database is substantial because the compound has been on the US market for more than a decade with continuous post-marketing surveillance. The labeled adverse effects include injection-site reactions (the most common reported event), arthralgia, peripheral edema, and elevations in IGF-1 levels.

The most clinically significant concern with tesamorelin and other GHRH analogs is glucose metabolism. Growth hormone has counter-regulatory effects on insulin signaling, and chronic elevation of growth hormone activity can affect insulin sensitivity and glucose tolerance. The Egrifta label includes warnings about monitoring glucose parameters during treatment. In the approval trials, treated subjects showed small mean increases in glucose and HbA1c relative to placebo, generally not clinically significant in the studied population but a documented effect that requires monitoring in chronic use.8

Other labeled warnings address use in patients with active malignancy (because IGF-1 elevation may theoretically affect tumor growth) and in patients with hypersensitivity to mannitol (an excipient in the formulation). The complete safety profile is documented in the FDA-approved prescribing information.

Tesamorelin compared to other GHRH-axis compounds

The three compounds most commonly compared in the GHRH-analog category are sermorelin (29 amino acids, short half-life, voluntarily withdrawn from FDA approval, now 503A compounded), tesamorelin (44 amino acids with N-terminal modification, extended half-life, currently FDA-approved as Egrifta), and CJC-1295 (29 amino acids with DAC modification, very long half-life, currently Category 2 and not legally compoundable).

Tesamorelin's distinguishing characteristics are its FDA approval status and its longer-acting kinetics, which support a simpler dosing schedule than sermorelin. Its specific effect on visceral adipose tissue, documented in the approval trials, is also a feature without an exact equivalent in the sermorelin literature. The two compounds activate the same receptor and produce overlapping but not identical effects.

Current regulatory and access status

Egrifta and Egrifta SV remain FDA-approved and commercially available by prescription in the US. The compound is also available in 503A-compounded preparations for off-label use, supplied by licensed compounding pharmacies on physician prescription. Several large compounding pharmacies maintain tesamorelin in their formularies.

The compound's regulatory position is stable. It is not on any of the FDA's Category 2 lists. It is not the subject of recent enforcement action. Its access pathway is well-established. Brands operating in the embedded telehealth and 503A pharmacy model can incorporate tesamorelin into their formularies under the same general legal framework as any other off-label compounded medication.

What a reader should retain

Tesamorelin is an FDA-approved GHRH analog with a specific approved indication and a substantial off-label clinical use base. Its mechanism is established. Its body composition effects in the studied populations are documented. Its safety profile, after more than a decade of post-marketing data, is reasonably well-characterized. The compound's combination of regulatory clarity and clinical maturity makes it one of the most settled peptides in the current integrative medicine catalog, alongside sermorelin and the FDA-approved PT-141.

The compound's broader role in the future US peptide therapy landscape will depend on how the integrative medicine and longevity markets develop and on how the FDA's evolving regulatory framework treats off-label use of approved peptides relative to compounded peptide preparations. The compound itself is unlikely to change. The market context around it is the variable that is in motion.

Footnotes

1. Falutz J, Allas S, Blot K, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." N Engl J Med. 2007;357(23):2359-2370. Early clinical pharmacology data on tesamorelin. https://pubmed.ncbi.nlm.nih.gov/18057338/
   
2. FDA approval announcement for Egrifta (tesamorelin), November 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000Approv.pdf [verify URL]
3. Falutz J, Potvin D, Mamputu JC, et al. "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension." J Acquir Immune Defic Syndr. 2010;53(3):311-322. https://pubmed.ncbi.nlm.nih.gov/20101189/
   
4. FDA approval of Egrifta SV (tesamorelin) supplemental new drug application, 2019. [verify reference]
5. Stanley TL, Falutz J, Marsolais C, et al. "Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin." Clin Infect Dis. 2012;54(11):1642-1651. https://pubmed.ncbi.nlm.nih.gov/22495074/ [verify]
6. FDA, "Understanding Unapproved Use of Approved Drugs 'Off Label'." https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
   
7. Stanley TL, Fourman LT, Feldpausch MN, et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." Lancet HIV. 2019;6(12):e821-e830. https://pubmed.ncbi.nlm.nih.gov/31611038/
   
8. Egrifta (tesamorelin for injection) prescribing information. FDA-approved label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505lbl.pdf [verify current label URL]
9. Frier Levitt, "Regulatory Status of Peptide Compounding in 2025," January 2026. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/